Acorai

About Acorai

Acorai is a Swedish medical device company developing a non-invasive solution for heart failure management, a condition affecting over 64 million people globally. Founded in 2019 by Filip Peters, who serves as CEO, along with co-founders Jakob Gelberg (CTO), Kasper Bourdette (COO), and Matthew Mace (CSO), the company is headquartered in Helsingborg. Peters, a serial medtech entrepreneur with a background in machine learning, invented the core technology. Gelberg previously co-founded the charity app Bigheart, while Mace founded the data and analytics firm BlueGranite.

The company's core product is the Acorai Heart Monitor, a handheld device utilizing the patented SAVE Sensor System. This system combines seismic, acoustic, visual, and electrical sensors with machine learning algorithms to provide non-invasive measurements of intracardiac pressure, such as pulmonary artery pressure. The objective is to offer healthcare professionals a tool for more accurate and timely assessment of a patient's hemodynamic and congestion status, comparable to invasive methods. This data-driven approach aims to personalize patient treatment, reduce hospital readmission rates, and lower healthcare costs. The device is intended for use by healthcare professionals in clinical settings.

Acorai operates in the medtech market, with a business model centered on selling its device to hospitals and healthcare providers. The company has achieved significant milestones, including receiving FDA Breakthrough Device Designation in August 2023 and being selected for the FDA's TAP Pilot program, both of which are intended to streamline regulatory review. Acorai has raised a total of $9 million over three funding rounds, including grants and seed investments. Key investors include the European Innovation Council (EIC) Fund, Solardis Health Ventures, KHP Ventures, and Taipei Medical University. The company is conducting a large-scale global clinical study, CAPTURE-HF, across multiple countries to validate its technology and is targeting market access in the U.S. and Europe, with a commercial launch anticipated by 2026.